Lewis(y) antigen-mediated positive feedback loop induces and promotes chemotherapeutic resistance in ovarian cancer

Liu,Juanjuan; Zheng,Mingjun; Qi,Yue; Wang,Huimin; Liu,Miao; Liu,Qing; Lin,Bei

doi:10.3892/ijo.2018.4496

Lewis(y) antigen-mediated positive feedback loop induces and promotes chemotherapeutic resistance in ovarian cancer

Authors:
- Juanjuan Liu
- Mingjun Zheng
- Yue Qi
- Huimin Wang
- Miao Liu
- Qing Liu
- Bei Lin
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, China Medical University Shengjing Hospital, Shenyang, Liaoning 110004, P.R. China
Published online on: July 20, 2018 https://doi.org/10.3892/ijo.2018.4496
Pages: 1774-1786

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the association between Lewis(y) antigen and chemoresistance in ovarian cancer and to elucidate the underlying molecular mechanisms. Lewis(y) expression in chemoresistant ovarian cancer tissues and cells was detected by immunohistochemistry. α1,2‑fucosyltransferase (FUT1) expression in different ovarian cancer chemotherapy-resistant cells was analyzed by reverse transcription-quantitative PCR (RT-qPCR). Genes differentially expressed in the chemoresistant and sensitive groups were screened using a gene chip followed by validation using RT-qPCR and western blot analysis. We found that Lewis(y) and FUT1 expression in ovarian cancer cells was significantly increased following the induction of drug resistance. The positive expression rate and intensity of Lewis(y) in ovarian cancer chemoresistant tissues were also significantly higher than those in the sensitive group. Compared with the non-resistant cell lines, the differentially expressed genes were mainly enriched in the terms related to the transmembrane receptor protein tyrosine kinase signaling pathway and positive regulation of cell proliferation. Interaction network analysis predicted genes participating in the regulation of apoptotic processes. The highly differential expression of Annexin A4 (ANXA4), BCL2 interacting killer (BIK), transmembrane 4 L six family member 4 (TM4SF4) and pleckstrin homology-like domain family A member 1 (PHLDA1) was validated using RT-qPCR in ovarian cancer cell lines. Finally, ANXA4 expression was increased at both the mRNA and protein level in the drug‑resistant cells, and in addition, ANXA4 contained a Lewis(y) structure. The expression of Bcl-2 and other anti-apoptotic proteins increased with the increase of Lewis(y) expression. After blocking Lewis(y) using an antibody, the expression of the involved signaling pathway and apoptosis-related proteins decreased significantly. These findings provide strong evidence that Lewis(y) is a component of the structure of the ANXA4 membrane protein. Its overexpression can abnormally activate signaling pathways and regulate the expression of a number of factors, forming a positive feedback loop to induce the chemoresistance of ovarian cancer cells, and ultimately promoting the progression of ovarian cancer.

View Figures

View References

1	Markman M: Current standards of care for chemotherapy of optimally cytoreduced advanced epithelial ovarian cancer. Gynecol Oncol. 131:241–245. 2013. View Article : Google Scholar : PubMed/NCBI
2	Pliarchopoulou K and Pectasides D: Epithelial ovarian cancer: Focus on targeted therapy. Crit Rev Oncol Hematol. 79:17–23. 2011. View Article : Google Scholar
3	He S, Niu G, Shang J, Deng Y, Wan Z, Zhang C, You Z and Shen H: The oncogenic Golgi phosphoprotein 3 like overexpression is associated with cisplatin resistance in ovarian carcinoma and activating the NF-κB signaling pathway. J Exp Clin Cancer Res. 36:1372017. View Article : Google Scholar
4	Roberts CM, Tran MA, Pitruzzello MC, Wen W, Loeza J, Dellinger TH, Mor G and Glackin CA: TWIST1 drives cisplatin resistance and cell survival in an ovarian cancer model, via upregulation of GAS6, L1CAM, and Akt signalling. Sci Rep. 6:376522016. View Article : Google Scholar : PubMed/NCBI
5	Roseman S: Reflections on glycobiology. J Biol Chem. 276:41527–41542. 2001. View Article : Google Scholar : PubMed/NCBI
6	Iwamori M, Tanaka K, Kubushiro K, Lin B, Kiguchi K, Ishiwata I, Tsukazaki K and Nozawa S: Alterations in the glycolipid composition and cellular properties of ovarian carcinoma-derived RMG-1 cells on transfection of the α1,2-fucosyltransferase gene. Cancer Sci. 96:26–30. 2005. View Article : Google Scholar : PubMed/NCBI
7	Zhao Y, Lin B, Hao YY, Yan LM, Liu JJ, Zhu LC and Zhang SL: The effects of Lewis(y) antigen content on drug resistance to carboplatin in ovarian cancer line RMG-I. Prog Biochem Biophys. 35:1175–1182. 2008.
8	Zhang F, Liu J, Lin B, Liu Q, Zhao Y, Zhu L, Hao Y, Zhang S and Iwamori M: Increase in docetaxel-resistance of ovarian carcinoma-derived RMG-1 cells with enhanced expression of Lewis Y antigen. Int J Mol Sci. 12:7323–7334. 2011. View Article : Google Scholar : PubMed/NCBI
9	Liu J, Lin B, Hao Y, Qi Y, Zhu L, Li F, Liu D, Cong J, Zhang S and Iwamori M: Lewis y antigen promotes the proliferation of ovarian carcinoma-derived RMG-I cells through the PI3K/Akt signaling pathway. J Exp Clin Cancer Res. 28:1542009. View Article : Google Scholar : PubMed/NCBI
10	Hu Z, Gao J, Zhang D, Liu Q, Yan L, Gao L, Liu J, Liu D, Zhang S and Lin B: High expression of Lewis y antigen and CD44 is correlated with resistance to chemotherapy in epithelial ovarian cancers. PLoS One. 8:e572502013. View Article : Google Scholar : PubMed/NCBI
11	Gao J, Hu Z, Liu J, Liu D, Wang Y, Cai M, Zhang D, Tan M and Lin B: Expression of CD147 and Lewis y antigen in ovarian cancer and their relationship to drug resistance. Med Oncol. 31:9202014. View Article : Google Scholar : PubMed/NCBI
12	Zhu LC, Gao J, Hu ZH, Schwab CL, Zhuang HY, Tan MZ, Yan LM, Liu JJ, Zhang DY and Lin B: Membranous expressions of Lewis y and CAM-DR-related markers are independent factors of chemotherapy resistance and poor prognosis in epithelial ovarian cancer. Am J Cancer Res. 5:830–843. 2015.PubMed/NCBI
13	Hu Z, Gao S, Gao J, Hou R, Liu C, Liu J, Li B, Liu D, Zhang S and Lin B: Elevated levels of Lewis y and integrin α5β1 correlate with chemotherapeutic drug resistance in epithelial ovarian carcinoma. Int J Mol Sci. 13:15588–15600. 2012. View Article : Google Scholar
14	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔC(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
15	Zhu L, Hu Z, Liu J, Gao J and Lin B: Gene expression profile analysis identifies metastasis and chemoresistance-associated genes in epithelial ovarian carcinoma cells. Med Oncol. 32:4262015. View Article : Google Scholar
16	Iwamori M, Iwamori Y, Kubushiro K, Ishiwata I and Kiguchi K: Characteristic expression of Lewis-antigenic glycolipids in human ovarian carcinoma-derived cells with anticancer drug-resistance. J Biochem. 141:309–317. 2007. View Article : Google Scholar
17	Madjd Z, Parsons T, Watson NF, Spendlove I, Ellis I and Durrant LG: High expression of Lewis y/b antigens is associated with decreased survival in lymph node negative breast carcinomas. Breast Cancer Res. 7:R780–R787. 2005. View Article : Google Scholar : PubMed/NCBI
18	Gao L, Yan L, Lin B, Gao J, Liang X, Wang Y, Liu J, Zhang S and Iwamori M: Enhancive effects of Lewis y antigen on CD44-mediated adhesion and spreading of human ovarian cancer cell line RMG-I. J Exp Clin Cancer Res. 30:152011. View Article : Google Scholar : PubMed/NCBI
19	Yan LM, Lin B, Zhu LC, Hao YY, Qi Y, Wang CZ, Gao S, Liu SC, Zhang SL and Iwamori M: Enhancement of the adhesive and spreading potentials of ovarian carcinoma RMG-1 cells due to increased expression of integrin alpha5beta1 with the Lewis Y-structure on transfection of the alpha1,2-fucosyltrans-ferase gene. Biochimie. 92:852–857. 2010. View Article : Google Scholar : PubMed/NCBI
20	Tan M, Zhu L, Zhuang H, Hao Y, Gao S, Liu S, Liu Q, Liu D, Liu J and Lin B: Lewis Y antigen modified CD47 is an independent risk factor for poor prognosis and promotes early ovarian cancer metastasis. Am J Cancer Res. 5:2777–2787. 2015.PubMed/NCBI
21	Gao S, Liu Q, Wang X, Lin B and Zhang S: Effects of Lewis Y antigen on the gene expression of multiple drug resistance-associated proteins in human ovarian cancer RMG-I-H cells. Med Oncol. 27:960–967. 2010. View Article : Google Scholar
22	Wang C, Yan L, Wang Y, Lin B, Liu S, Li Q, Gao L, Zhang S and Iwamori M: Overexpression of Lewis(y) antigen protects ovarian cancer RMG-1 cells from carboplatin-induced apoptosis by the upregulation of Topo-I and Topo-II β. Anat Rec (Hoboken). 294:961–969. 2011. View Article : Google Scholar
23	Wang XQ, Sun P, O'Gorman M, Tai T and Paller AS: Epidermal growth factor receptor glycosylation is required for ganglioside GM3 binding and GM3-mediated suppression [correction of suppresion] of activation. Glycobiology. 11:515–522. 2001. View Article : Google Scholar : PubMed/NCBI
24	Liu JJ, Lin B, Hao YY, Li FF, Liu DW, Qi Y, Zhu LC, Zhang SL and Iwamori M: Lewis(y) antigen stimulates the growth of ovarian cancer cells via regulation of the epidermal growth factor receptor pathway. Oncol Rep. 23:833–841. 2010.PubMed/NCBI
25	Li FF, Liu JJ, Liu DW, Lin B, Hao YY, Cong JP, Zhu LC, Gao S, Zhang SL and Iwamori M: Lewis Y regulates signaling molecules of the transforming growth factor β path way in ovarian carcinoma derived RMG-I cells. Int J Oncol. 40:1196–1202. 2012. View Article : Google Scholar
26	Zhuang H, Gao J, Hu Z, Liu J, Liu D and Lin B: Co-expression of Lewis y antigen with human epididymis protein 4 in ovarian epithelial carcinoma. PLoS One. 8:e689942013. View Article : Google Scholar : PubMed/NCBI
27	Lee T, Guo K, Li S, Qin S and Liu S: Effects of ANXA4 on cell adhesive ability and expression of adhesion-related genes in hepatocellular carcinoma MHCC97H cell line. J Clin Trials. 31:588–591. 2013.
28	Matsuzaki S, Serada S, Morimoto A, Ueda Y, Yoshino K, Kimura T and Naka T: Annexin A4 is a promising therapeutic target for the treatment of platinum-resistant cancers. Expert Opin Ther Targets. 18:403–414. 2014. View Article : Google Scholar : PubMed/NCBI
29	Choi CH, Sung CO, Kim HJ, Lee YY, Song SY, Song T, Kim J, Kim TJ, Lee JW, Bae DS, et al: Overexpression of Annexin A4 is associated with chemoresistance in papillary serous adenocar-cinoma of the ovary. Hum Pathol. 44:1017–1023. 2013. View Article : Google Scholar : PubMed/NCBI
30	Lin LL, Huang HC and Juan HF: Revealing the molecular mechanism of gastric cancer marker Annexin A4 in cancer cell proliferation using exon arrays. PLoS One. 7:e446152012. View Article : Google Scholar : PubMed/NCBI
31	Kelly MP, Lee FT, Tahtis K, Smyth FE, Brechbiel MW and Scott AM: Radioimmunotherapy with alpha-particle emitting 213Bi-C-functionalized trans-cyclohexyl-diethylenetriamine-pentaacetic acid-humanized 3S193 is enhanced by combination with paclitaxel chemotherapy. Clin Cancer Res. 13:5604s–5612s. 2007. View Article : Google Scholar
32	Baldus SE, Mönig SP, Zirbes TK, Thakran J, Köthe D, Köppel M, Hanisch FG, Thiele J, Schneider PM, Hölscher AH, et al: Lewis(y) antigen (CD174) and apoptosis in gastric and colorectal carcinomas: Correlations with clinical and prognostic parameters. Histol Histopathol. 21:503–510. 2006.PubMed/NCBI
33	Azuma Y, Ito M, Taniguchi A and Matsumoto K: Expression of cell surface Lewis X and Y antigens and FUT4 mRNA is increased in Jurkat cells undergoing apoptosis. Biochim Biophys Acta. 1672:157–163. 2004. View Article : Google Scholar : PubMed/NCBI
34	Azuma Y, Kurusu Y, Sato H, Higai K and Matsumoto K: Increased expression of Lewis X and Y antigens on the cell surface and FUT 4 mRNA during granzyme B-induced Jurkat cell apoptosis. Biol Pharm Bull. 30:655–660. 2007. View Article : Google Scholar : PubMed/NCBI
35	Gao N, Liu J, Liu D, Hao Y, Yan L, Ma Y, Zhuang H, Hu Z, Gao J, Yang Z, et al: c-Jun transcriptionally regulates alpha 1, 2-fucosyltransferase 1 (FUT1) in ovarian cancer. Biochimie. 107:286–292. 2014. View Article : Google Scholar : PubMed/NCBI